Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Esophageal squamous cell carcinoma early screening marker based on metabonomics and kit thereof

A technology for esophageal squamous cell carcinoma and detection reagents, which is applied in the field of medicine and biology, can solve the problems of less than 2% detection rate of esophageal squamous cell carcinoma, no significant improvement in mortality rate, etc., achieves good diagnosis effect, good differentiation effect, and improves detection rate Effect

Pending Publication Date: 2021-10-01
THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because early patients have no specific symptoms, most patients are already in the middle and advanced stages when they see a doctor, and the detection rate of early esophageal squamous cell carcinoma is less than 2%, so that the mortality rate of the disease has not improved significantly in the high-incidence areas of esophageal squamous cell carcinoma in China
However, there are no effective preparations for early diagnosis and general screening of esophageal squamous cell carcinoma. If metabolic markers that can be used for screening of esophageal squamous cell carcinoma can be screened out, it will be a powerful impetus to the status quo of early diagnosis of esophageal squamous cell carcinoma in my country. It opens up new avenues for drug screening and precision medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Esophageal squamous cell carcinoma early screening marker based on metabonomics and kit thereof
  • Esophageal squamous cell carcinoma early screening marker based on metabonomics and kit thereof
  • Esophageal squamous cell carcinoma early screening marker based on metabonomics and kit thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Screening of serum differential metabolic markers for esophageal squamous cell carcinoma

[0032] 1. Collection of serum samples

[0033] A total of 79 serum samples were collected from the Henan Key Laboratory of Esophageal Squamous Cell Carcinoma, the First Affiliated Hospital of Zhengzhou University, including 39 cases of normal human serum (normal control group) and 40 serum samples of patients with esophageal squamous cell carcinoma (esophageal squamous cell carcinoma group). Sera from 39 cases of normal people came from the normal physical examination population of the physical examination center of the laboratory's cooperative hospital, without any tumor-related evidence. Forty sera from patients with esophageal squamous cell carcinoma were obtained from patients with early stage (stage 0+stage I) esophageal squamous cell carcinoma confirmed by histopathology, and none of them received radiotherapy or chemotherapy.

[0034] 2. Experimental method

[...

Embodiment 2

[0057] Example 2: Evaluation of the ability of differential metabolite diagnosis to distinguish patients with esophageal squamous cell carcinoma from healthy people

[0058] 1. The ability of a single differential metabolite diagnosis to distinguish patients with esophageal squamous cell carcinoma from normal people:

[0059] N-o-cresyl glycine, D-sorbose in the esophageal squamous cell carcinoma group (40 patients with esophageal squamous cell carcinoma) and normal control group (39 normal persons) serum samples detected based on UPLC-Q / TOF-MS in Example 1 The content data of alcohol and N-acetyl-D-mannosamine were analyzed, and the receiver operating curve (ROC curve) was used to evaluate the ability of each differential metabolite to diagnose and distinguish patients with esophageal squamous cell carcinoma from normal people.

[0060] The ROC curve of N-o-cresyl glycine, D-sorbitol, and N-acetyl-D-mannosamine alone to distinguish patients with esophageal squamous cell carci...

Embodiment 3

[0084] Example 3: Application of three differential metabolites in the screening of esophageal squamous cell carcinoma

[0085] 1. Collection of serum samples

[0086] In addition, the sera of 20 patients with esophageal squamous cell carcinoma and 20 normal people were selected from the Key Open Laboratory of Esophageal Squamous Cell Carcinoma in Henan Province, the First Affiliated Hospital of Zhengzhou University; among them, the sera of 20 patients with esophageal squamous cell carcinoma came from early (Stage 0+Stage I) patients with esophageal squamous cell carcinoma did not receive radiotherapy or chemotherapy. The serum of 20 normal people came from the normal physical examination population of the physical examination center of the laboratory's cooperative hospital, without any evidence of tumor-related.

[0087] 2. Analysis method

[0088] According to the UPLC-Q / TOF-MS technology described in Example 1, three metabolites N-o-cresyl glycine, D-sorbitol, N-acetyl -D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medical biology, and discloses an esophageal squamous cell carcinoma early screening marker based on metabonomics and a kit thereof. The marker for screening the esophageal squamous cell carcinoma, provided by the invention, is at least one of N-o-tolueneglycine, D-sorbitol and N-acetyl-D-mannosamine, and a detection reagent of the marker can be used for preparing a product for screening the esophageal squamous cell carcinoma. The invention also provides a kit for screening esophageal squamous carcinoma. The kit contains a detection reagent for detecting the marker. According to the kit, the esophageal squamous cell carcinoma, especially the early esophageal squamous cell carcinoma, can be effectively detected by detecting the expression levels of N-o-tolueneglycine, D-sorbitol and N-o-tolueneglycine in human serum; and when the three markers are combined, the detection sensitivity reaches up to 92.2%, the specificity reaches 98.0%, and the kit can be used for large-scale screening of asymptomatic crowds in high-incidence areas of esophageal squamous carcinoma and is beneficial to screening and early discovery of asymptomatic high-risk crowds.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and specifically discloses metabonomics-based markers for early diagnosis of esophageal squamous cell carcinoma and a kit thereof. Background technique [0002] Esophageal squamous cell carcinoma is one of the six most common malignant tumors in the world, with significant regional distribution differences and family aggregation. my country is the country with the highest incidence and mortality of esophageal squamous cell carcinoma in the world. There are about 500,000 cases of cancer patients, more than half of which occur in China. In China, half of the patients occurred in the Taihang Mountain area at the junction of Henan, Hebei, and Shanxi provinces. Among them, Linxian County, Henan Province has the highest incidence and mortality rate of esophageal squamous cell carcinoma in the world, which is a hundred times higher than that in Western countries. Esophageal squamous cell ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N30/02
CPCG01N30/02
Inventor 宋昕王立东陈亚杰王盼盼杨苗苗胡景峰钟侃徐瑞华魏梦霞韩文莉雷玲玲赵学科
Owner THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com